CC BY-NC-ND 4.0 · International Journal of Practical Otolaryngology 2019; 02(01): e11-e17
DOI: 10.1055/s-0039-1692466
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Investigation of Recurrent Cases of Head and Neck Cancer after Initial Treatment

Ryosuke Kitoh
1   Department of Otorhinolaryngology, Shinshu University School of Medicine, Matsumoto, Nagano, Japan
,
Kentaro Mori
1   Department of Otorhinolaryngology, Shinshu University School of Medicine, Matsumoto, Nagano, Japan
,
Shin-ichi Usami
1   Department of Otorhinolaryngology, Shinshu University School of Medicine, Matsumoto, Nagano, Japan
› Author Affiliations
Further Information

Publication History

18 January 2019

27 March 2019

Publication Date:
14 June 2019 (online)

Abstract

The optimal follow-up strategy for patients with head and neck cancer after primary treatment is still under debate. This study aimed to review the data of patients with recurrence and evaluate our follow-up strategy. Patients with head and neck cancer who underwent surgery or chemoradiotherapy as the primary treatment between 2012 and 2016 were enrolled. All the patients were carefully followed up at our institution via intensive clinical examination and routine computed tomography (CT) and positron emission tomography (PET)/CT. Recurrence was detected in 20 of the patients treated by surgery and 25 of 96 patients treated by chemoradiotherapy. In more than 90% of the patients, recurrence occurred within 2 years of the primary treatment. Among the patients with recurrence, 11 showed local recurrence, 17 showed regional recurrence, and 17 others showed distant metastasis. In almost all patients with distant metastases, recurrence was detected using CT or PET/CT, whereas among the patients with local or regional recurrence, recurrence was detected based on the patients' complaints and their clinical examination results. Only salvage surgery was observed to be associated with disease-free survival after recurrence. Thus, analysis of the recurrence patterns and appropriate surveillance can result in improved salvage treatment for patients with recurrence.

 
  • References

  • 1 2018 Japanese Clinical Practice Guidelines for Head and Neck Cancer (Japanese Society for Head and Neck Cancer edition). Tokyo: Kanehara & Co. Ltd.; 2018: 85
  • 2 National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers; 2018
  • 3 Schwartz DL, Barker Jr J, Chansky K. , et al. Postradiotherapy surveillance practice for head and neck squamous cell carcinoma—too much for too little?. Head Neck 2003; 25 (12) 990-999
  • 4 Meregaglia M, Cairns J, Licitra L, Bossi P. The use of intensive radiological assessments in routine surveillance after treatment for head and neck cancer: an economic evaluation. Eur J Cancer 2018; 93: 89-98
  • 5 Guerra EN, Rêgo DF, Elias ST. , et al. Diagnostic accuracy of serum biomarkers for head and neck cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol 2016; 101: 93-118
  • 6 O'Meara WP, Thiringer JK, Johnstone PA. Follow-up of head and neck cancer patients post-radiotherapy. Radiother Oncol 2003; 66 (03) 323-326
  • 7 Kissun D, Magennis P, Lowe D, Brown JS, Vaughan ED, Rogers SN. Timing and presentation of recurrent oral and oropharyngeal squamous cell carcinoma and awareness in the outpatient clinic. Br J Oral Maxillofac Surg 2006; 44 (05) 371-376
  • 8 D'Cruz AK, Vaish R, Kapre N. , et al; Head and Neck Disease Management Group. Elective versus therapeutic neck dissection in node-negative oral cancer. N Engl J Med 2015; 373 (06) 521-529
  • 9 Asakage T. Neck treatment in early tongue cancer. Oto-Rhino-Laryngology Tokyo 2017; 60: 218-225
  • 10 Imai T, Satoh I, Matsumoto K. , et al. Retrospective observational study of occult cervical lymph-node metastasis in T1N0 tongue cancer. Jpn J Clin Oncol 2017; 47 (02) 130-136
  • 11 Yoo J, Henderson S, Walker-Dilks C. Evidence-based guideline recommendations on the use of positron emission tomography imaging in head and neck cancer. Clin Oncol (R Coll Radiol) 2013; 25 (04) e33-e66
  • 12 Fletcher JW, Djulbegovic B, Soares HP. , et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 2008; 49 (03) 480-508
  • 13 Mehanna H, Wong WL, McConkey CC. , et al; PET-NECK Trial Management Group. PET-CT Surveillance versus neck dissection in advanced head and neck cancer. N Engl J Med 2016; 374 (15) 1444-1454
  • 14 Ferris RL, Blumenschein Jr G, Fayette J. , et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016; 375 (19) 1856-1867
  • 15 Ferris RL, Blumenschein Jr G, Fayette J. , et al. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol 2018; 81: 45-51